What Does Being Heterozygous for Factor V Leiden Mean?
Being heterozygous for Factor V Leiden means you have inherited one copy of a genetic mutation (G1691A) that makes your blood approximately 3-4 times more likely to clot abnormally, though your lifetime risk of actually developing a blood clot remains relatively low at around 10%. 1
Understanding the Genetics
Factor V Leiden heterozygosity means you carry one mutated copy and one normal copy of the Factor V gene. This single mutation impairs your body's ability to break down Factor V, a clotting protein, because it resists inactivation by activated protein C—a natural anticoagulant in your blood 2. This creates a mild hypercoagulable (increased clotting tendency) state.
Your Actual Risk Numbers
The penetrance (likelihood you'll actually develop problems) is low for heterozygotes 1:
- Lifetime risk of venous thromboembolism (VTE): approximately 10%
- Risk by age 60: about 6.5%
- Odds ratio for first VTE compared to non-carriers: 3.49 (95% CI: 2.46-4.96) 3
To put this in perspective: if you're an asymptomatic family member of someone with Factor V Leiden, your annual VTE incidence is around 0.1-0.15% without the mutation versus a modestly higher rate with heterozygous Factor V Leiden 3.
Clinical Implications
For Recurrent Clots
If you've already had one unprovoked VTE, being heterozygous for Factor V Leiden does increase your risk of recurrence, but the magnitude is small compared to the baseline risk from having had a clot in the first place 3. Importantly, heterozygous Factor V Leiden alone (without other mutations) does not typically warrant lifelong anticoagulation after a first VTE 4.
Critical Exception: Double Heterozygosity
If you carry both Factor V Leiden AND the prothrombin G20210A mutation (compound heterozygosity), your risk profile changes dramatically—with a 2.6-fold increased risk of recurrence compared to Factor V Leiden alone, and you should be considered for lifelong anticoagulation 5. The risk is particularly high (5.4-fold) if your first event was spontaneous 5.
High-Risk Situations
Women-specific risks are particularly important 6:
- Oral contraceptives significantly amplify clotting risk
- Pregnancy carries increased VTE risk, though evidence for heterozygotes specifically is insufficient 3
- Female double heterozygotes develop VTE nearly a decade earlier than non-carriers (mean age 44 vs. 53 years) 6
Surgical/transplant contexts: Heterozygous Factor V Leiden significantly increases risk of thrombotic complications in renal transplant recipients, including early graft loss 7, 8.
Important Caveats
Testing Utility is Limited
Current guidelines emphasize that for most VTE patients, genetic testing has low clinical utility because treatment decisions don't typically depend on genotype 1. The 2025 ACMG technical standard notes there is no consensus on using genotype to determine treatment regimens for most VTE patients 1.
When Testing May Be Useful
Testing has acknowledged clinical utility in specific circumstances 1:
- Pregnant individuals with previous VTE and positive family history
- Preoperative assessment for high-risk procedures (like transplantation)
- Family members of index cases to guide counseling about situational risks
Homozygous vs. Heterozygous
While homozygous carriers (two mutated copies) have substantially higher risk—odds ratio of 17.84 for first VTE 3—recent evidence suggests that VTE management should not differ significantly based on whether you're heterozygous or homozygous 4. The key determinant is whether you've had a clot, not the specific genotype.
Bottom Line for Management
Most heterozygous Factor V Leiden carriers who have never had a clot require no treatment, only awareness of situational risks (surgery, immobilization, hormonal contraception, pregnancy). If you've had one unprovoked VTE, standard anticoagulation duration (typically 3-6 months) applies unless you have additional risk factors like compound heterozygosity with prothrombin mutation 5, 9.